CALIFORNIA | LOCAL
August 24, 1999
North American Scientific Inc., Chatsworth, announced net income for the company increased to $981,000 for the quarter ended July 31, 1999, compared with net income of $420,000 for the same period of the previous year. Net sales increased 90% to $3.4 million compared with net sales of $1.8 million. North American Scientific manufactures a broad line of products for medical therapeutic and diagnostic, environmental and research applications.
December 29, 1992
North American Scientific Inc. in North Hollywood said it has signed a long-term agreement with the International Economic Federation in Moscow from whom NASI will buy Russian-made radioisotopes and other radiation materials. Shipments are expected to begin in early 1993 and will exceed $300,000 in value. NASI makes a broad line of low-level radiation sources and standards for applications in environmental monitoring, nuclear medicine, biotechnology and aerospace.
September 16, 1997
North American Scientific Inc. reported a net income of $41,200 for its fiscal third quarter, compared with $115,800 a year ago. The North Hollywood company posted sales for the quarter, which ended July 31, of $820,400, down 2% from $836,300 the year before. For the nine months, the company reported net profit of $220,200, down 16% from $261,500 in 1996. Sales were $2.6 million, up 30% from $2.0 million in 1996.
CALIFORNIA | LOCAL
October 3, 2000
North American Scientific Inc., Chatsworth, said it plans to complete the acquisition of Theseus Imaging Corp. later this month. The terms of the purchase have been renegotiated since the merger agreement was announced in October 1999. Theseus shareholders will receive up to 350,000 shares of NASI common stock in exchange for all of Theseus common stock. In addition NASI will assume all of Theseus obligations including $7.5 million advanced to Theseus by NASI for research and development.
November 11, 1997
North American Scientific Inc. has received FDA approval to market its second-generation iodine-125 brachytherapy radiation source for treating prostate cancer, the North Hollywood-based company said. The company has filed for patent protection for the enhanced drug, which will be marketed by Mentor Corp. under the trade name IoGold. In February, North American Scientific announced FDA approval of its initial source design, also marketed by Mentor Corp.